A recent survey of 367 healthcare executives–representing payers, providers, and pharmaceutical companies–suggests that most of them are not prepared for the changing economic conditions and the evolving prospects for reform: Only 30 percent of executives representing the health care industry in the United States say their companies are ready for reform and changing economic conditions… [...]

Filed under: Health Policy, Innovation, Pharma/Biotech | No Comments »

Pfizer’s Plavix, the second best-selling drug in the world, now has a formidable rival on the market. The more potent antiplatelet prasugrel, made by Eli Lilly & Co., was just approved by the FDA and Lilly’s shares rose 32 cents, or 1%, to $33.32. As I had written in my previous blog entry on this [...]

Filed under: Pharma/Biotech | No Comments »